AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31918324
Drug: Model with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Model with improved variables (progesterone and oestrogen receptor expression, method of sample extraction)
Trial: 31918531
Drug: Energy Conservation
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy Conservation plus Problem-Solving Therapy
Trial: 31919092
Drug: Inhibitor development
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitor development in patients with SHB
Trial: 31919092
Drug: Allergic reactions
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergic reactions in inhibitor patients
Trial: 31919092
Drug: Genotype association
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype association with inhibitors
Trial: 31919404
Drug: FOLFIRINOX every
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX every 2 weeks (adapted dose in stage two)
Trial: 31920571
Drug: KINVIS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KINVIS therapy combined with conventional therapeutic exercise (TherEX) for 10 days
Trial: 31920571
Drug: KINVIS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KINVIS therapy combined with conventional therapeutic exercise (TherEX)
Trial: 31920733
Drug: Lanicemine, NMDA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanicemine, NMDA receptor antagonist, dosage and duration not available
Trial: 31922084
Drug: SC +
RxNorm normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC + Enhanced Program (SC + EP; 8 skill-building cores, monthly support sessions, targeted diet/physical activity strategies)
Trial: 31922545
Drug: OAC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC with vitamin K antagonists
Trial: 31922545
Drug: OAC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC with vitamin K antagonists, clinically significant depressive symptoms (PHQ-2 ≥ 3)
Trial: 31923098
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (n=1617)
Trial: 31923098
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (n=2658)
Trial: 31923098
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (n=1810)
Trial: 31923800
Drug: NGS matched
RxNorm normalized name: NG
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGS matched therapy
Trial: 31924241
Drug: Reparixin 1000
RxNorm normalized name: Réparixine
DrugBank: Reparixin (DB12614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reparixin 1000 mg orally three times daily for 21 days before surgery
Trial: 31928530
Drug: C3 administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C3 administration in GC cell lines
Trial: 31928530
Drug: C3 blocker
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: C3 blocker pre-incubation
Trial: 31928530
Drug: JAK2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: JAK2 inhibitor pre-treatment
Trial: 31929554
Drug: Incentive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incentive and information tracks of the intervention; specific details on dosage and duration not available.
Trial: 31929554
Drug: Community-based recruitment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based recruitment strategy; specific details on dosage and duration not available.
Trial: 31929554
Drug: Management of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management of inputs at the facility and patient level; specific details on dosage and duration not available.
Trial: 31930057
Drug: Sertraline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (75 mg/day)
Trial: 31930095
Drug: Oral Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Chinese Medicine (CM) herbal medication administered twice daily for eight weeks.
Trial: 31930374
Drug: Ambroxol therapy
RxNorm normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol therapy (1.26 g per day)
Trial: 31931024
Drug: Dendritic cell
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell (DC)-based active cellular immunotherapy using high hydrostatic pressure-killed cancer cells derived from NSCLC cell lines.
Trial: 31932137
Drug: gp120-NefTat/AS01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gp120-NefTat/AS01 vaccine
Trial: 31932382
Drug: Linezolid treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid treatment, specific dosage and duration not available
Trial: 31932515
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg oral tablets
Trial: 31932515
Drug: Erenumab 70
RxNorm normalized name: Erenumab 70 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab 70 mg subcutaneous monthly
Trial: 31932515
Drug: Erenumab 140
RxNorm normalized name: Erenumab 140 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab 140 mg subcutaneous monthly
Trial: 31932515
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg oral tablets and Erenumab
Trial: 31934594
Drug: Subacromial 10-mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial 10-mL 2% lidocaine injection
Trial: 31934594
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection (no contents injected)
Trial: 31934829
Drug: Radiofrequency ablation
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency ablation (RFA) treatment, 88 sessions from January 2008 to April 2014.
Trial: 31936256
Drug: Questionnaire items
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Questionnaire items addressing Oral Health Locus of Control (OHLOC)
Trial: 31937310
Drug: Caverstem 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caverstem 1.0 low dose
Trial: 31937310
Drug: Caverstem 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caverstem 1.0 high dose
Trial: 31937474
Drug: CAREN system
RxNorm normalized name: 3-carene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAREN system (8 sessions, twice weekly for 4 weeks)
Trial: 31937616
Drug: GDC-0084 (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-0084 (45 mg/day)
Trial: 31937616
Drug: GDC-0084 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-0084 (various doses)
Trial: 31937616
Drug: GDC-0084 (≥45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDC-0084 (≥45 mg/day)
Trial: 31941657
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in the 1970s
Trial: 31941657
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in the 1980s
Trial: 31941657
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in the 1990s
Trial: 31941953
Drug: Fingolimod (FTY)
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fingolimod (FTY) treatment
Trial: 31942173
Drug: Cilostazol 200
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol 200 mg once daily for 2 years
Trial: 31942173
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg once daily for 2 years
Trial: 31942430
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection (IVI) of anti-VEGF (bevacizumab or ranibizumab) followed by a loose treat and extend regimen.
Trial: 31942430
Drug: Rescue therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue therapy of aflibercept (Group 2).
Trial: 31942430
Drug: Initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial treatment with three loading doses of either bevacizumab or ranibizumab.
Trial: 31943126
Drug: Near-infrared fluorescence
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Near-infrared fluorescence imaging with indocyanine green (ICG) administered intravenously at 0.3 mg/kg bodyweight.
Trial: 31943126
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of white-light and NIR-ICG.
Trial: 31943691
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (PPI) use
Trial: 31943974
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg (with dose escalation to 300 mg)
Trial: 31943974
Drug: Secukinumab (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab (any dose)
Trial: 31945475
Drug: Post-bronchodilator response
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-bronchodilator response (BDR) measurements
Trial: 31948451
Drug: BPI-9016M (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPI-9016M (100 mg to 800 mg, QD dosing for 28 days)
Trial: 31950432
Drug: YAZ (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YAZ (3 mg drospirenone/20 μg ethinyl estradiol)
Trial: 31952975
Drug: Cemiplimab 3
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 3 mg/kg intravenously over 30 min every 2 weeks for up to 96 weeks
Trial: 31954100
Drug: Oral colistin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral colistin and neomycin decontamination
Trial: 31954624
Drug: Nazartinib (EGF816)
RxNorm normalized name: Lazertinib
DrugBank: Nazartinib (DB16250)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nazartinib (EGF816) 150 mg once daily (tablet)
Trial: 31956341
Drug: Diabetic foot
RxNorm normalized name: Zostrix Diabetic Foot Pain
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diabetic foot ulcer treatment
Trial: 31956421
Drug: Dynamic LED
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic LED lighting for 4 weeks in addition to standard treatment
Trial: 31956421
Drug: Static LED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static LED lighting for 4 weeks in addition to standard treatment
Trial: 31956432
Drug: Intravitreal ziv-aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ziv-aflibercept (IVZ) 1.25 mg
Trial: 31956961
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tofogliflozin
Trial: 31956961
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg glimepiride
Trial: 31958302
Drug: NGT-1-hour-high (glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGT-1-hour-high (glucose ≥8.6 mmol/L)
Trial: 31958302
Drug: NGT-1-hour-normal (glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGT-1-hour-normal (glucose <8.6 mmol/L)
Trial: 31958302
Drug: One-hour glucose
RxNorm normalized name: ONE TOUCH (GLUCOSE) METER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-hour glucose concentration ≥8.6 mmol/L
Trial: 31959034
Drug: hs-cTnT levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT levels >14 ng/L at anthracycline completion
Trial: 31960589
Drug: Amphetamine-type stimulants
RxNorm normalized name: AMPHETAMINE LIKE STIMULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine-type stimulants use in the past six months
Trial: 31960953
Drug: Peroperative carcinoembryonic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peroperative carcinoembryonic antigen (CEA)-specific fluorescence imaging during cytoreductive surgery-hyperthermic intraperitoneal chemotherapy
Trial: 31961766
Drug: Lenvatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib plus pembrolizumab (200 mg intravenously every 3 weeks)
Trial: 31961766
Drug: Lenvatinib 20
RxNorm normalized name: LENVATINIB 20MG DAILY DOSE PACK,10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib 20 mg/d plus pembrolizumab (recommended phase II dose)
Trial: 31961766
Drug: Lenvatinib 24
RxNorm normalized name: lenvatinib 24 MG Daily Dose 30 Day Supply Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib 24 mg/d plus pembrolizumab (initial dose level)
Trial: 31961766
Drug: Subsequent dose-de-escalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent dose-de-escalation cohort (lenvatinib 20 mg/d plus pembrolizumab)
Trial: 31961826
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg mirabegron for 4 weeks
Trial: 31961829
Drug: Mirabegron treatment
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron treatment
Trial: 31964784
Drug: CUE-101, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CUE-101, a novel therapeutic fusion protein composed of a human leukocyte antigen (HLA) complex, an HPV16 E7 peptide epitope, reduced affinity human IL2 molecules, and an effector attenuated human IgG1 Fc domain.
Trial: 31969330
Drug: ABBV-838 (3+3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-838 (3+3 design) intravenously starting from 0.6 mg/kg up to 6.0 mg/kg for 3-week dosing intervals (Q3W), continued for up to 24 months.
Trial: 31969338
Drug: Decitabine and
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine and Vorinostat with chemotherapy (vincristine, dexamethasone, mitoxantrone, PEG-asparaginase)
Trial: 31971541
Drug: Talimogene laherparepvec
RxNorm normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Talimogene laherparepvec (T-VEC) plus pembrolizumab (200-mg flat dose) intravenously; T-VEC first dose ≤4 mL × 106 PFU/mL, subsequent doses ≤4 mL × 108 PFU/mL, injected into palpable tumor site(s) on day 1 of each 21-day cycle.
Trial: 31971567
Drug: IV posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV posaconazole 300 mg
Trial: 31971567
Drug: IV posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV posaconazole 400 mg
Trial: 31972008
Drug: rs9349379-G allele
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rs9349379-G allele
Trial: 31972008
Drug: Zibotentan (ETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zibotentan (ETA antagonist)
Trial: 31972009
Drug: ST2 (>26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST2 (>26 ng/mL) in children age 10 years or younger
Trial: 31972009
Drug: TNFR1 (>3441
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFR1 (>3441 pg/mL) in children age 10 years or younger
Trial: 31972009
Drug: REG3α (>25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REG3α (>25 ng/mL) in children age 10 years or younger
Trial: 31972009
Drug: ST2 (>26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST2 (>26 ng/mL) in patients older than age 10 years
Trial: 31972009
Drug: TNFR1 (>3441
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNFR1 (>3441 pg/mL) in patients older than age 10 years
Trial: 31972009
Drug: REG3α (>25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REG3α (>25 ng/mL) in patients older than age 10 years
Trial: 31977002
Drug: Avadomide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avadomide (3 to 5 mg) administered on continuous or intermittent schedules until unacceptable toxicity, disease progression, or withdrawal.
Trial: 31977002
Drug: Avadomide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avadomide (3 to 5 mg) administered on intermittent 5/7-day schedule.
Trial: 31978210
Drug: Daratumumab 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab 16 mg/kg administered by IV infusion once weekly for weeks 1 to 8, every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter until progression or unacceptable toxicity, for up to 24 months.
Trial: 31978210
Drug: Daratumumab 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab 16 mg/kg administered by IV infusion.
Trial: 31978221
Drug: Crovalimab (680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crovalimab (680 mg; 4 mL), administered subcutaneously once every 4 weeks
Trial: 31978886
Drug: ROTEM-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROTEM-based therapy
Trial: 31980466
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks for 2 years or until progression, intolerable toxicity, or physician/patient decision
Trial: 31982162
Drug: Early BM-MNC
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Early BM-MNC treatment (5-7 days after AMI)
Trial: 31982162
Drug: Late BM-MNC
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Late BM-MNC treatment (3-4 weeks after AMI)
Trial: 31982610
Drug: Endoscopic eradication
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoscopic eradication therapy (EET) leading to complete eradication of intestinal metaplasia (CE-IM)
Trial: 31984235
Drug: LDL-c less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-c less than 70 mg/dL
Trial: 31984235
Drug: LDL-c of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-c of 100 ± 10 mg/dL
Trial: 31984451
Drug: Nevanimibe HCl
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Nevanimibe (DB16254)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevanimibe HCl at doses ranging from 1.6 mg/kg/day to 158.5 mg/kg/day
Trial: 31985467
Drug: Donepezil 10 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 10 mg/day
Trial: 31986140
Drug: Nifurtimox eflornithine
RxNorm normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifurtimox eflornithine combination therapy (NECT)
Trial: 31986169
Drug: Periodontal scaling
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal scaling and root planing (SRP) treatment
Trial: 31987969
Drug: Conformal photon
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conformal photon radiation therapy (RT)
Trial: 31988230
Drug: Potentially inappropriate
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially inappropriate prescribing (PIP) at admission and discharge, assessed using the newest screening tool for older persons' potentially inappropriate prescriptions.
Trial: 31988230
Drug: Adverse drug
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse drug reactions (ADRs) during hospitalisation.
Trial: 31988230
Drug: Polypharmacy, defined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy, defined as the number of chronic prescribed medications.
Trial: 31988972
Drug: Delafloxacin 300
RxNorm normalized name: delafloxacin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delafloxacin 300 mg twice daily
Trial: 31989725
Drug: Intrathecal Baclofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal Baclofen (ITB) therapy
Trial: 31989856
Drug: Paclitaxel-Eluting Stent
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel-Eluting Stent (Eluvia Drug-Eluting Stent)
Trial: 31992396
Drug: Hypoglossal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoglossal nerve stimulation (HNS) therapy
Trial: 31992396
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with OSA (conservative therapy or observation)
Trial: 31992606
Drug: Step-based care
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step-based care model comprising psychotherapy, medication management, family support/education, peer support, and vocational/educational support.